| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.34 | 6e-22 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.36 | 3e-21 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.29 | 4e-16 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.27 | 1e-15 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.41 | 1e-14 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-10 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-10 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.32 | 6e-10 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.2 | 5e-09 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-09 |